Stock of the Day

Biogen (BIIB)

$216.65

-$1.85 (-0.8%)

Market Cap: $32.28B

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

• Biogen Inc. recently reported earnings per share (EPS) of $3.60, significantly exceeding analysts' expectations, indicating strong financial performance and potential for future growth.
• The company has set its fiscal year 2026 guidance at an EPS range of 12.000-13.000, suggesting confidence in its future profitability and growth trajectory.
• Biogen Inc. has a market capitalization of approximately $32.73 billion, reflecting its substantial size and stability in the biotechnology sector.
• Recent revenue growth of 3.4% year-over-year demonstrates the company's ability to increase sales, which is a positive indicator for investors looking for growth opportunities.
• The current stock price is around $227.79, which is within a reasonable range compared to its twelve-month high, suggesting potential for appreciation.

Biogen Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

• Despite recent earnings success, the company reported a decline in EPS from $5.47 in the same quarter last year, which may raise concerns about long-term profitability.
• Biogen Inc. has a relatively high price-to-earnings (P/E) ratio of 39.20, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
• The company has a net margin of 8.32%, which, while positive, may suggest limited profitability compared to competitors in the biotechnology sector.
• Analysts have mixed ratings on the stock, with one "Sell" rating and several "Hold" ratings, indicating uncertainty about its future performance.
• Biogen Inc. has a beta of 0.17, suggesting lower volatility compared to the market, which may limit potential high returns for investors seeking aggressive growth.

Recent News

• Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) (financialpost.com)
• Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) (globenewswire.com)
• Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease (finance.yahoo.com)
• Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients (quiverquant.com)
• Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease (globenewswire.com)
• Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks (finance.yahoo.com)
• Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks (insidermonkey.com)
• Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? (finance.yahoo.com)
• FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now (finance.yahoo.com)
• 3 Reasons to Sell BIIB and 1 Stock to Buy Instead (finance.yahoo.com)